"Preclinical Evaluation of Group B Neisseria meningitidis and Escherichia coli K92 Capsular Polysaccharide-Protein Conjugate Vaccines in Juvenile Rhesus Monkeys."

According to the authors' abstract of an article published in Infection and Immunity, "We reported the first use of group B meningococcal conjugate vaccines in a nonhuman primate model (S.J.N. Devi, C.E. Frasch, W. Zollinger, and P.J. Snoy, p. 427-429, in J.S. Evans, S.E. Yost, M.C.J. Maiden, and I.M. Feavers, ed., Proceedings of the Ninth International Pathogenic Neisseria Conference, 1994). Three different group B Neisseria meningitidis capsular polysaccharide (B PS)-protein conjugate vaccines and an Escherichia coli K92 capsular polysaccharide-tetanus toxoid (K92-TT) conjugate vaccine are here evaluated for safety and relative immunogenicities in juvenile rhesus monkeys...

Want to see the full article?

• Purchase this article for only $3.00